Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 13, 2013

View Archived Issues

Phase II clinical trial data presented for new monoclonal antibody for type 1 diabetes

Novel nonhuman primate model developed for HCV infection

Synergistic effects on cognition seen with ZSET-1446 and galantamine, rivastigmine and memantine

Agios Pharmaceuticals patents new IDH1 inhibitors for cancer

Chinese group synthesizes novel agents for cancer

Spinifex Pharmaceuticals designs novel angiotensin AT2 receptor antagonists

Scientists at Merck Patent divulge new GCN2 inhibitors

EnVivo Pharmaceuticals synthesizes new gamma-secretase modulators

T-VEC shows potential as a treatment option for melanoma patients in phase III trials

Biocon launches ALZUMAb in India

DengueCide receives FDA orphan drug designation

TherapeuticsMD begins phase I study of its vaginal estradiol suppository

University of Alberta collaborates with BGI Shenzhen on cancer screening technology

Shionogi profiles achievements of first quarter of fiscal 2013

Phase III Allovectin trial does not meet efficacy endpoints

Advanomics receives second grant for Adva-27a

Cardium Therapeutics reports on Excellagen potential in birth defects

Galectin Therapeutics' GR-MD-02 receives FDA fast track designation

Celldex Therapeutics expands phase II ReACT study in recurrent glioblastoma

Immunomedics advances solid tumor ADC programs to phase II

Tekmira Pharmaceuticals begins phase I/II TKM-PLK1 trial

First human implantation of map3 cellular allogeneic bone graft completed

Avanir Pharmaceuticals and Merck enter co-promotion agreement for Januvia

Maxygen's shareholders approve dissolution of the company

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...